FOR IMMEDIATE RELEASE
4 April 2004
Ipsat Therapies Oy Completes ?7M Financing Round and Strengthens Board of
Helsinki, Finland (4 April 2005) -- Ipsat Therapies, a Finnish biopharmaceutical company with a novel approach to fighting hospital acquired infections and antibiotic resistance, today announced it closed a ?7
million private placement bringing the total amount raised since inception to more than ?19 million. The
round was led by Bio Fund Management Oy with Finnish Industry Investment Ltd, the Varma Mutual Pension Insurance Company, and Sitra also investing. The Company will use the proceeds for research and development of its product portfolio, primarily its Phase IIb Proof of Concept clinical trial for P1A, a recombinant enzyme for the prevention of antibiotic-associated diarrhea, antibiotic resistance, and gut disturbance. Ipsat Therapies is also actively pursuing alliances with partners to expedite commercialization.
With the financing, Ipsat gained several new members of the Board of Directors including an Executive Chairman, Dr Wolfgang Pieken, CEO of MWG Biotech AG and a founding partner of Ventac Partners, a European and a US partnership dedicated to the nurturing of biotech companies from start-up to commercial success; Aki Prihti, Investment Director of Bio Fund; Riitta Jääskeläinen, Investment Director of Finnish Industry Investment Ltd; Mr Pauli Marttila; and Dr Kai Lindevall. Dr Pieken has a strong background in the life science industry both in research and management including NeXstar Pharmaceuticals and Proligo LLC, where he was CEO.
“We are proud to have completed our planned ?7 million financing,” Dr Marion Carson, CEO of Ipsat
Therapies commented. “Given the current market challenges faced by biotechnology companies, we consider the closing of this investment with high profile investors is a mark of confidence in our commercial strategy, clinical progress to date, and highly experienced pharmaceutical team.”
Dr Pieken, the newly elected Executive Chairman commented, "I am delighted to work with the Ipsat team to develop the Company’s highly promising approach to fighting antibiotic resistance and severe side effects to its full commercial potential.”
In addition, Mr Aki Prihti of Bio Fund said: “We are excited to become a shareholder in Ipsat Therapies.
The Company has a unique approach in the field of infectious diseases and these financial resources will take the lead product through Phase IIb and move the products towards commercialization.”
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Dr Marion Carson Mr Aki Prihti
CEO Investment Director
Ipsat Therapies Bio Fund Management Oy rdViikinkaari 4, Mikonkatu 4, 3 Floor
FIN-00790 Helsinki P.O. Box 164,00101 Helsinki, Finland
Finland Tel: +358 9 2514 4628
Tel: +358 9 319 36 520 Email: firstname.lastname@example.org
www.biofund.fi Email: email@example.com
NOTES TO EDITORS:
About Ipsat Therapies
Ipsat Therapies is committed to fighting infectious diseases and prolonging the life of antibiotics by preventing the development of secondary infections and anti-microbial resistance. Ipsat believes that such an approach will complement other efforts in infectious diseases where new antibiotic discovery has not kept pace with the increasing development of resistance to older agents. Founded in 1999 the Company is based in the Helsinki Business and Science Park and currently employs 20 persons. Based on its proprietary position in using recombinant enzymes targeted to intestinal antibiotic residue to protect the microflora during antibiotic treatment, this novel approach has the potential to preserve colonization resistance to pathogen overgrowth while preventing the development of anti-microbial resistance. Using its expertise in drug development and experience in commercialization, the Company is advancing its products through clinical trials. Phase IIa studies with the first product were carried out in 2004 and Phase IIb will commence in 2005. Patient groups most likely to benefit from these products are the elderly, the immunosuppressed, and those on chronic antibiotic treatment.
Ipsat Therapies will present the results of the first Phase IIa trials at the 15th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen, Denmark, (ECCMID 2005) on April 5th. Additional information is available on Ipsat Therapies? web site at www.ipsat-ther.com About Bio Fund Management Oy
Bio Fund Management Oy (BioFund) is one of the leading European venture capital management companies investing solely in the Life Sciences. The main sectors of BioFund include Pharmaceuticals, Medical Technologies, Nutrition and Environmental Technologies. BioFund has an international scope, with its main focus centered in Europe, especially in the Nordic countries. The company manages the Bio Fund Ventures I, II, II and BFV II Follow-on venture capital funds, whose combined commitments total ?195 million.
About Finnish Industry Investment Ltd
Finnish Industry Investment Ltd is a government-owned investment company. It engages in equity capital investment and invests in venture capital funds, private equity funds and directly in selected target companies. Finnish Industry Investment Ltd is administered by the Ministry of Trade and Industry. The outstanding commitments of FII total ?282 million at the end of 2004.
About Varma Mutual Pension Insurance Company
Varma Mutual Pension Insurance Company is the largest private sector pension insurer in Finland; entrusted with pension funds of more than ?21.2 billion Varma is the biggest investor in Finland. The
company is an important actor in the capital markets, as well as being a significant real estate investor. About Sitra
Sitra, the Finnish National Fund for Research and Development, is an independent public foundation under the supervision of the Finnish Parliament. Its activities are designed to promote the economic prosperity of the Finnish people. The means used to achieve this are research and training, innovative projects and business development, and venture capital. Sitra’s activities are financed by the yield from its own endowment capital and the return on its venture-capital investments.